ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CLYM / earnings
ACRS (19) IRWD (59) NVCT (37) GERN (28) ⌘ Pro Terminal →

Climb Bio Inc. (CLYM) Next Earnings Date & Expected ±12.5% Move

$10.25 -0.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.22

Climb Bio Inc. (CLYM) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $588.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLYM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLYM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Climb Bio Inc. (NASDAQ: CLYM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $10.25 (-0.77% 1D, market cap $588.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLYM ranks #856 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLYM compare to ACRS and IRWD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLYM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACRS (Aclaris Therapeutics Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $584.4M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C- grade (59/100 RQD, P/E 24.9x, ROIC 85.0%, cap $578.3M). Among the 5-stock peer group, IRWD leads on earnings multiple (24.9x) while IRWD leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLYM?
▼

Per CLYM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001768446), Climb Bio Inc. generated $0 in revenue, -$59.9M in net income, and -$54.5M in free cash flow against $167.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.22 (-0.33%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (4)Whales (6)SEC (10)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.5% Base Target
$19 Bull$9 Base$7 Bear
📬 FREE CLYM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLYM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY CLYM SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (36% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Whale & Options Positioning+6/20 pts (21% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$10.31+4.8% Next Q
Q2 (-2Q)
33
Grade E$10.80-11.4% Next Q
Q3 (-1Q)
31
Grade E$9.57+7.1% Next Q
Current
28
Grade E$10.25-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLYM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLYM currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.34) and Max Pain ($10.76) forces dealer call-delta covering toward $19.25.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLYM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CLYM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.28 Expected Swing
$8.97 (-12.5%)Spot $10.25$11.53 (+12.5%)
MODEL EARNINGS SETUP GAUGE

CLYM Quantitative Pre-Earnings Setup: 28/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (28/100)Model Risk Weight (72/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$0-$59.9M-$54.5M52%
FY 20242024-12-31$0-$73.9M-$15.6M52%
FY 20232023-12-31$0-$35.1M-$20.6M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLYM)

  • ✓Walkthrough of CLYM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CLYM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.78%📐 HORIZONTAL RANGE
2026-11-03O $10.33H $10.33L $10.25C $10.25VOL 708.8K
RES: $22.15SUP: $8.42SMA50: $12.34SMA200: $10.44
$19.33$15.18$11.03$6.88$2.73RES $22.15SUP $8.42$10.252026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLYM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLYM Butterfly Map → + Track CLYM →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLYM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLYM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLYM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLYM)

Health Care Rank #856 of 1016 ⚔️ ACRS vs CLYM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLYM vs. ACRS, IRWD, NVCT, GERN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Climb Bio Inc. (CLYM) ranks #856 by composite RQD confidence (28/100, grade E) and #418 by equity capitalization ($588.7M). Within this direct 5-issuer industry benchmark cohort, IRWD leads on earnings valuation at 24.9x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with CLYM at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CLYM ACTIVE
Climb Bio Inc.
E 28/100 — — -35.0% -0.77% $588.7M Benchmark Subject
ACRS
Aclaris Therapeutics Inc.
E 19/100 — 73.3% -35.0% -0.50% $584.4M /acrs-vs-clym →
IRWD
Ironwood Pharmaceuticals Inc. (Class A)
C- 59/100 24.9x — 85.0% -3.31% $578.3M /irwd-vs-clym →
NVCT
Nuvectis Pharma Inc.
D- 37/100 — — -35.0% -0.48% $602.7M /nvct-vs-clym →
GERN
Geron Corporation
E 28/100 — — -20.2% -5.47% $574.6M /gern-vs-clym →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001768446

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Climb Bio Inc. (CLYM) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$59.9M, operating cash flow of -$54.4M, and free cash flow of -$54.5M (-250.5% YoY). On the balance sheet, CLYM closed FY2025 with $167.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$59.9M -$54.4M -$54.5M $167.7M —
FY2024 (FY) 2024-12-31 $0 -$73.9M -$15.6M -$15.6M $217.2M —
FY2023 (FY) 2023-12-31 $0 -$35.1M -$20.6M -$20.6M — —

3. CLYM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLYM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Climb Bio Inc. (NASDAQ: CLYM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $10.25 (-0.77% 1D, market cap $588.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLYM ranks #856 in composite RQD confidence.

How does CLYM compare to ACRS and IRWD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLYM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACRS (Aclaris Therapeutics Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $584.4M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C- grade (59/100 RQD, P/E 24.9x, ROIC 85.0%, cap $578.3M). Among the 5-stock peer group, IRWD leads on earnings multiple (24.9x) while IRWD leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLYM?

Per CLYM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001768446), Climb Bio Inc. generated $0 in revenue, -$59.9M in net income, and -$54.5M in free cash flow against $167.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLYM trading relative to its 50-day, 200-day, and 52-week technical levels?

CLYM last traded at $10.25 (-0.77% on volume of 708,763 shares), positioning the stock -16.94% below its 50-day simple moving average ($12.34) and -1.82% below its 200-day simple moving average ($10.44). Across its 52-week range of $1.63 to $18.33, CLYM sits at the 51.6% percentile with a 14-day RSI of 44.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.97 to $11.53).

CLYM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is CLYM's next earnings date?

Based on SEC filing cadence, Climb Bio Inc. (CLYM)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is CLYM stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for CLYM, spanning a range between $8.97 and $11.53.

Direct Sub-Reports: CLYM RQD Cockpit CLYM 12M Forecast CLYM Earnings & Move CLYM Dividends & DRIP CLYM Insiders & 13F CLYM Whale Options CLYM Profit Sankey CLYM News & Why
ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CLYM — Climb Bio Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:34:42Z

Roarable Rating Brief: What This Means to a Prospective Investor

The per the Roarable RQD rating, CLYM carries an RQD Score of 29 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars, each scored out of 20, are:

  • Fundamental Cash Engine: 4 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is -9.19%. This is the weakest pillar and indicates the business is consuming rather than generating cash on a return basis.
  • Whale 13F Flow: 6 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The score is moderate-to-weak, and the source data does not provide the underlying 13F holdings detail.
  • Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the second-weakest score, suggesting limited insider-side conviction signals in the rating's inputs.
  • Macro Regime Fit: 6 / 20. Per the Roarable RQD rating, beta is 1.0 with a sector-sensitivity read. The score is moderate-to-weak.
  • Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. This is the strongest pillar, but it is still only half-credit.

Taken together, the pillars indicate that the rating's weakest inputs are operating cash generation and insider conviction, while the balance sheet offers partial support. For a prospective investor evaluating the stock today, the implication is that the rating frames CLYM as high-risk on current fundamentals. Upside drivers would have to come from catalysts that the cash-engine and insider pillars do not yet reflect. Valuation tradeoffs are difficult to assess because the source data lacks earnings-based multiples, so the price of $10.33 cannot be benchmarked against earnings. This is an educational reading of the rating, not personalized financial advice.

Business

Climb Bio Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe specific products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M in each of the three listed fiscal years, indicating no reported revenue in the source period. The company's market capitalization is $0.6B per the profile.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-67.9M$-59.9MN/A$-54.5M$35.7MN/A
FY 2024$0.0M$-82.0M$-73.9MN/A$-15.6M$87.2MN/A
FY 2023$0.0M$-40.3M$-35.1MN/A$-20.6MN/AN/A

Per the SEC financials, the company reported operating losses and net losses in all three periods, with FY 2025 operating loss at $-67.9M and net loss at $-59.9M. Per the Roarable RQD rating, ROIC is -35%, and per the market data, gross, operating, and net margins are each 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. Cash declined from $87.2M in FY 2024 to $35.7M in FY 2025 per the SEC financials.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, six items reference CLYM, all rated YELLOW with a MARKET WIRE impact label. Headlines include a TradingView stock-price report, a Yahoo Finance piece on sector performance versus CLYM, a Seeking Alpha analysis referencing a 12-week dosing interval, a Simply Wall St analyst-forecast page, a Yahoo Finance item reporting a Deutsche Bank initiation at Buy citing an autoimmune pipeline, and an NKyTribune piece describing CLYM as a speculative biotech. The 12-week dosing interval and autoimmune pipeline are the most specific clinical-related references in the feed. Per the Butterfly Supply-Chain Graph, the supply_chain field is NONE, with no butterfly links and no proprietary signals.

Open Questions

  • What are the company's specific products, clinical programs, and regulatory milestones, given that the source data references a pipeline and dosing interval but no detail?
  • What is the source of reported cash decline and the cash runway implied by FY 2025 cash of $35.7M against a $-54.5M FCF figure?
  • Why are EPS, P/E, and EV/EBITDA unavailable, and how should valuation be assessed without earnings-based multiples?
  • What drove the 52-week range spanning $1.63 to $18.33, and what institutional or insider activity accompanied that move?
  • What is the basis for the Deutsche Bank Buy initiation referenced in the news feed, and does that view appear in the analyst data?

CLYM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Climb Bio Inc. (CLYM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLYM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLYM Bull vs. Bear Conversation Board — What's Your Call at $10.25?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLYM 🐻 67% BEARISH CONVICTION
1. Pick Your Side on CLYM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $9.09 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CLYM (E • RQD 29/100) a Buy at $10.33?

Welcome to the CLYM (Climb Bio Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $8.57 (-17.0%)
Spot @ $10.33

Pump the brakes on CLYM — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CLYM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Climb Bio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $11.88 (+15.0%)
Spot @ $10.33

CLYM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CLYM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $10.33 (52-wk range $1.63 - $18.33), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%